| Tanekia Gatlin, | |
|
4109 Highway 98 W, Summit, MS 39666-9132 | |
| (601) 276-3900 | |
| Not Available |
| Full Name | Tanekia Gatlin |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 4109 Highway 98 W, Summit, Mississippi |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316151830 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | S3114 (Mississippi) | Primary |
| Provider Name | Fox Rehab Agency Ms Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1336839000 PECOS PAC ID: 2769841782 Enrollment ID: O20230707002981 |
News Archive
Florida is falling short when it comes to supporting policies and passing legislation to prevent and reduce suffering and death from cancer. According to the latest edition of How Do You Measure Up?: A Progress Report on State Legislative Activity to Reduce Cancer Incidence and Mortality, Florida did not measure up to policy recommendations in any of the nine issue areas ranked.
During a Friday speech in California, President Barack Obama touted the health law's benefits - highlighting the Golden State's progress so far - in his effort to encourage young people and Latinos to sign up for coverage that will be available through new online insurance exchanges.
Regenerative medicine company Mesoblast Limited (ASX: MSB) today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes – neovascular ("wet") Age-related Macular Degeneration (AMD).
Bioniche Life Sciences Inc. and Paladin Labs Inc. today announced the official closing of the various agreements associated with a comprehensive strategic collaboration to refinance and increase Bioniche's debt, provide new equity, and enter into the first licensing deal for Bioniche's Phase III bladder cancer product - Urocidin.
With over 1,400 products in active development, the innovation pipeline for cardiovascular disease (CVD) is extensive, with four key CVD indications – hypertension, heart failure, dyslipidemia and thrombosis – now accounting for around half of all pipeline innovation, according to GBI Research, a recognized leader in providing business information and analytics.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tanekia Gatlin, 4109 Highway 98 W, Summit, MS 39666-9132 Ph: (601) 276-3900 | Tanekia Gatlin, 4109 Highway 98 W, Summit, MS 39666-9132 Ph: (601) 276-3900 |
News Archive
Florida is falling short when it comes to supporting policies and passing legislation to prevent and reduce suffering and death from cancer. According to the latest edition of How Do You Measure Up?: A Progress Report on State Legislative Activity to Reduce Cancer Incidence and Mortality, Florida did not measure up to policy recommendations in any of the nine issue areas ranked.
During a Friday speech in California, President Barack Obama touted the health law's benefits - highlighting the Golden State's progress so far - in his effort to encourage young people and Latinos to sign up for coverage that will be available through new online insurance exchanges.
Regenerative medicine company Mesoblast Limited (ASX: MSB) today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes – neovascular ("wet") Age-related Macular Degeneration (AMD).
Bioniche Life Sciences Inc. and Paladin Labs Inc. today announced the official closing of the various agreements associated with a comprehensive strategic collaboration to refinance and increase Bioniche's debt, provide new equity, and enter into the first licensing deal for Bioniche's Phase III bladder cancer product - Urocidin.
With over 1,400 products in active development, the innovation pipeline for cardiovascular disease (CVD) is extensive, with four key CVD indications – hypertension, heart failure, dyslipidemia and thrombosis – now accounting for around half of all pipeline innovation, according to GBI Research, a recognized leader in providing business information and analytics.
› Verified 2 days ago
Rise And Shine Therapy Collective, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1044 Singleton Dr, Summit, MS 39666 Phone: 601-810-3705 | |
Elizabeth Fuller, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4109 Highway 98 W, Summit, MS 39666 Phone: 601-276-3900 | |
Katherine Barker, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4109 Highway 98 W, Summit, MS 39666 Phone: 601-847-7040 | |
Brina Oscar, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4109 Highway 98 W, Summit, MS 39666 Phone: 601-276-3900 | |
Kendria Coleman, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4109 Hwy 98 W, Summit, MS 39666 Phone: 601-276-3900 | |
Kyndall Rushing, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4109 Highway 98 W, Summit, MS 39666 Phone: 601-276-3900 Fax: 601-276-3939 | |
Scott Schilling, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4109 Highway 98 W, Summit, MS 39666 Phone: 601-276-3900 |